Drug intelligence / Profile preview

DJS-003

Development stage: Unknown
Lead developer: DJS Antibodies
Modality: Antibody-Based Therapeutics
Administration: Oral

Overview

DJS-003 is an investigational antibody therapeutic discovered using DJS Antibodies’ proprietary HEPTAD platform for the treatment of inflammatory diseases, acting as a modulator of G protein–coupled receptor (GPCR) signaling pathways to regulate pathological inflammation.[3][5][11] Developed preclinically by DJS Antibodies prior to the company’s acquisition by a larger pharma group, the program was designed to exploit a novel GPCR target in chronic inflammatory indications but was discontinued before reaching late-stage clinical development.[3][5][11]

Beyond the preview

Go deeper on DJS-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DJS-003.

Explore the full profile